Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05333549 · ClinicalTrials.gov registry record · Phase 2
Istradefylline for Parkinson Disease With Cognitive Impairment
A Phase 2 study, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT05333549 is a Phase 2 study that has completed, run by Virginia Commonwealth University. The registered enrollment target is 15 participants.
The verdict
NCT05333549, a Phase 2 study, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine whether istradefylline improves cognition in individuals with Parkinson disease with cognitive impairment.
Interventions
- DRUG Istradefylline medication
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2022-07-18 |
| Est. Completion | 2025-06-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05333549
The ClinicalTrials.gov registry entry for NCT05333549 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Istradefylline medication is the first listed.
NCT05333549 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05333549 about?
NCT05333549 is a clinical study titled "Istradefylline for Parkinson Disease With Cognitive Impairment". The purpose of this research study is to determine whether istradefylline improves cognition in individuals with Parkinson disease with cognitive impairment.
What is the current status of trial NCT05333549?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2022-07-18. Estimated completion is 2025-06-09.
What interventions are being tested in trial NCT05333549?
The interventions under investigation include: Istradefylline medication (DRUG).
Who is sponsoring clinical trial NCT05333549?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.